Novartis and Idenix Pharmaceuticals, Inc. . Click cluster in furtherance of more info. Announced today the European agreement in reference to telbivudine (LTD600) for approval as a underived therapy for patients affected by persistent mucous colitis B (chb), a potentially fatal complaint estimated on route to tinge more than three million commoners chic europe1 and and so 350 million ancestry worldwide. . .